Emerging Trends in Endometriosis Treatment - Review

Warren B. Nothnick, Xuan Zhang
In: Current Women's Health Reviews · 2008 · vol. 4(3) , pp. 188–199 · doi:10.2174/157340408785821746 · W1994690027
article OA: closed CC0
Full text JSON View on OpenAlex View at publisher
⚙ AI-generated summary by qwen3.7-flash, 2026-09-06 ⓘ

This review discusses current medical management of endometriosis and its shortcomings, emphasizing emerging research on TNF inhibitors as potential alternatives to hypoestrogenic therapies for developing future therapeutic targets.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

⚙ AI-generated deep summary by qwen3.7-flash, 2026-09-06 · read from full text ⓘ

This review examines the limitations of current medical management for endometriosis, which relies on inducing a hypoestrogenic state that causes significant side effects despite promoting disease regression. The authors highlight the necessity for novel therapeutic targets and specifically evaluate emerging research involving tumor necrosis factor-alpha inhibitors as potential alternatives to existing treatments. The paper also discusses other promising areas such as matrix metalloproteinases, aromatase, and angiogenesis in the context of future drug development. This paper is centrally about endometriosis — specifically reviewing current treatment shortcomings and exploring new pharmacological targets like TNF inhibitors.

Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works

Abstract

Endometriosis is an enigmatic, debilitating disease which affects as many as 15% of all women of reproductive age and is characterized by pelvic pain and infertility. Current treatment regimes used to manage the disease do so by inducing a hypoestrogenic state. While the absence of circulating estrogen levels lead to a regression of the disease, this hypoestrogenism also induces many unpleasant side-effects. As such, these and other shortcomings of current drug therapies emphasize their limitations and the necessity for the development of novel endometriosis treatments. In this review, current therapies for medical management of endometriosis are discussed as are their shortcomings. Potential target areas which may be attractive alternatives to current therapies are also reviewed. Emphasis is placed upon the emerging research using TNF inhibitors, their potential benefits over current treatment regimes and the development of future potential therapeutic targets.
Full text 1,103 characters · extracted from oa-doi-fallback · 2 sections · click to expand

Abstract

Endometriosis is an enigmatic, debilitating disease which affects as many as 15% of all women of reproductive age and is characterized by pelvic pain and infertility. Current treatment regimes used to manage the disease do so by inducing a hypoestrogenic state. While the absence of circulating estrogen levels lead to a regression of the disease, this hypoestrogenism also induces many unpleasant side-effects. As such, these and other shortcomings of current drug therapies emphasize their limitations and the necessity for the development of novel endometriosis treatments. In this review, current therapies for medical management of endometriosis are discussed as are their shortcomings. Potential target areas which may be attractive alternatives to current therapies are also reviewed. Emphasis is placed upon the emerging research using TNF inhibitors, their potential benefits over current treatment regimes and the development of future potential therapeutic targets.

Keywords

Endometriosis, treatment, tumor necrosis factor-alpha, matrix metalloproteinase, aromatase, angiogenesis 19

Text is read by the "Ask this paper" AI Q&A widget below. Extraction quality varies by source — PMC NXML preserves structure cleanly, OA-HTML may include some navigation residue, and OA-PDF can have broken hyphenation. The publisher copy (via DOI) is the canonical version.

My notes (saved in your browser only)

⚙ Ask this paper AI returns verbatim quotes from the full text · source: oa-doi-fallback ⓘ

Answers must be backed by verbatim quotes from this paper's full text. Hallucinated quotes are dropped automatically; if no verbatim passage answers the question, we say so. How this works

Condition tags

endometriosisinfertility

Citation neighborhood (no data yet)

We don't have any in-corpus citations linked to this paper yet. The paper's references may be in our DB but unresolved to ``paper_id`` (resolution happens at ingest when the cited DOI matches a row we already have). Run the cross-source citation reconcile pass to retry.

Source provenance

openalex
last seen: 2026-06-10T17:14:06.276822+00:00
License: CC0 · commercial use OK